The transactions highlighted below are representative of Greenhill engagements. In addition, the Firm has completed many engagements that were not publicly-disclosed.
Recent Transactions
Sort By
08-Dec-21
Pending
Undisclosed
Target:
Pet Circle
Acquiror:
Various global growth investors, including TDM Growth Partners, Prysm Capital, AirTree Ventures and Baillie Gifford
Advising Pet Circle, Australia’s leading online specialty pet company, on its unicorn Series C funding round, which included a A$125m primary capital raise
12-Nov-21
Undisclosed
Target:
Grupo Totalmédia
Acquiror:
Consortium of Private Investors Led by the Management Team
Advised Explorer Investments on the sale of Grupo Totalmédia, the leading specialist logistics player in Iberia operating in two-man home delivery, assembly and installation of furniture, heavy goods and groceries as well as the distribution of autoparts and leaflets
10-Nov-21
Undisclosed
Target:
Bell's Brewery
Acquiror:
Lion / Kirin
Advised Lion, one of Australasia’s leading beverage companies and a wholly owned subsidiary of Japanese conglomerate Kirin Holdings, on the acquisition of Bell’s Brewery, a leading US independent craft brewery
28-Oct-21
Pending
$217 million
Target:
Ferrovial Servicios
Acquiror:
Portobello Capital
Advised Portobello Capital, a leading Spanish private equity firm with more than $1.75bn AuM, on the acquisition through a carve out process of a controlling stake in Ferrovial Servicios, a leading infrastructure service business in Spain owned by Ferrovial
05-Oct-21
$175 million
Target:
Kao Data Ltd
Acquiror:
Infratil Ltd
Advised Kao Data Ltd, which is jointly owned by Legal & General Group PLC and Noé Group subsidiary Hockham, on raising an initial £120m-£130m growth capital commitment from Infratil Ltd with the objective of creating a £500m data centre platform
20-Sep-21
Undisclosed
Target:
Faes Farma, flagship product Bilastine
Acquiror:
Hikma Specialty USA INC
Advised Faes Farma in the signing of a long-term license agreement for its flagship product Bilastine with Hikma Specialty USA INC, a subsidiary of Hikma Pharmaceuticals PLC, for the United States of America
08-Sep-21
Undisclosed
Target:
Hydrogen Technology & Energy Corporation (HTEC)
Acquiror:
I Squared Capital
Advising I Squared Capital, an independent global infrastructure investment manager, on its acquisition of a 35% equity interest in HTEC, a privately-held leader in the hydrogen energy transition
27-Jul-21
Undisclosed
Target:
Pulsant Limited
Acquiror:
Antin Infrastructure Partners
Advised Antin Infrastructure Partners on its acquisition of Pulsant from Oak Hill and Scottish Equity Partners. Pulsant is a hybrid cloud specialist, with a nationwide network of 10 data centres across the UK delivering secure, scalable and resilient cloud, colocation and networking services
13-Jul-21
$94 million
Target:
Youfoodz Holdings Limited
Acquiror:
HelloFresh SE
Advised Youfoodz Holdings Limited, a leading provider of fresh, ready-made meals and other convenience food products, on its cash sale to HelloFresh SE via scheme of arrangement
01-Jul-21
Undisclosed
Target:
The Natural Fruit Company
Acquiror:
Fremman Capital
Advised Fremman on the acquisition of The Natural Fruit Company, a leading European producer and distributor of citrus fruits (both conventional and organic) including oranges, lemons, tangerines, grapefruit and persimmon fruit
30-Jun-21
Pending
Undisclosed
Target:
Deltalab
Acquiror:
SCG Packaging Public Company Limited
Advising Deltalab, a leading Spanish laboratory solutions provider with dedicated manufacturing capacity, on the sale of the company to SCG Packaging Public Company Limited, the largest integrated packaging and paper company in Southeast Asia
28-Jun-21
Pending
Undisclosed
Target:
Portfolio of 16 European Consumer Healthcare brands from Sanofi
Acquiror:
STADA Arzneimittel AG
Advising Sanofi, a leading global player in the Consumer Healthcare market, on the divestiture of a portfolio of 16 European Consumer Healthcare brands to STADA, a German pharmaceutical and consumer healthcare company owned by Bain Capital and Cinven
14-Jun-21
Pending
Undisclosed
Target:
300 MWp solar PV portfolio in Iberia from Alten
Acquiror:
Matrix Renewables
Advising Alten Energías Renovables (“Alten”), a global Independent Power Producer (IPP), on the sale of a solar PV portfolio of 300MWp in late stage of development across Spain and Portugal to Matrix Renewables, the renewable energy platform backed by global alternative asset manager TPG. In addition, Matrix Renewables and the Alten’s Management Team have agreed to enter a Joint Development Agreement (“JDA”) to further develop an additional 2GW of solar PV and storage assets across Iberia
07-Jun-21
Undisclosed
Target:
Rights to General, Right Guard and Dry Idea brands
Acquiror:
N/A
Advised Henkel on its brand divestment program (including the sale of the General, Right Guard and Dry Idea brands)
17-May-21
Pending
$275 million
Target:
Bruc Energy, one of the largest renewable energy platforms in Spain with c.4 GWp of Solar PV assets under operation, construction and development
Acquiror:
Universities Superannuation Scheme (“USS”)
Advising Bruc OPT Energy Partners (“BROP”), a renewable energy JV owned by OPTrust and Mr. Juan Béjar, on the sale of a 50% stake in Bruc Energy, one of the largest renewable energy platforms in Spain with c.4 GWp of Solar PV assets under operation, construction and development, to funds managed by Universities Superannuation Scheme (“USS”), the largest pension scheme by assets in the UK
10-May-21
Pending
N/A
Target:
International Flavors & Fragrances, Inc.’s Fruit Preparations business
Acquiror:
Frulact Serviços Partilhados, SA
Advised International Flavors & Fragrances on the divestiture of its European-based Fruit Preparation business to Frulact Serviços Partilhados, SA
29-Mar-21
Undisclosed
Target:
Worley’s Capital Projects Advisory business
Acquiror:
TSA Management
Advised ASX-listed Worley Limited on the sale of its Capital Projects Advisory business, a market leading provider of public infrastructure advisory services in Australia, New Zealand and Southeast Asia, to TSA Management (a portfolio company of Quadrant Private Equity)
18-Mar-21
$750 million
Target:
Canopy Growth Corporation
Acquiror:
King Street Capital Management, L.P.
Advised Canopy Growth, a leading diversified cannabis company, on its US$750 million term loan financing with King Street Capital Management, L.P.
19-Feb-21
$33 million
Target:
Acacia Pharma Group plc
Acquiror:
N/A
Advised Acacia Pharma Group plc, a US headquartered commercial stage biopharmaceutical company incorporated in England and listed in Belgium, on its placing of 10m new ordinary shares at a price of €2.70 per share
01-Feb-21
$292 million
Target:
Sunwing Airlines and Sunwing Vacations
Acquiror:
Canada Enterprise Emergency Funding Corp.
Advised Sunwing, a leading Canadian travel company and leisure airline, on its C$375mm financing under the Large Employer Emergency Financing Facility (LEEFF) program administered by the Canada Enterprise Emergency Funding Corp. and overseen by the Government of Canada
30-Oct-20
$142 million
Target:
Youfoodz Holdings Limited
Acquiror:
N/A
Advised Youfoodz Holdings Limited, a leading provider of fresh, ready-made meals and other convenience food products, on its initial public offering on the Australian Securities Exchange (ASX)
04-Oct-20
Undisclosed
Target:
Cosmetic applications endolysin
Acquiror:
L’Oréal
Advised Micreos, a fast-growing biotechnology company, on a long-term license agreement with L’Oréal for one of Micreos’ phage-based active ingredients, SA.100
29-Jul-20
$NA
Target:
Integrated supplier of preserved and frozen vegetables
Acquiror:
ACON Agri Investments S.L.
Advised ACON Agri Investments S.L., a special purpose vehicle of ACON Investments LLC, on the acquisition of Grupo Alsur, a leading integrated supplier of preserved and frozen vegetables with operations in Spain and Peru
11-Jun-20
$760 million
Target:
CSM Bakery Solutions
Acquiror:
Rhône Group
Advised the Ad-Hoc Group of First Lien and Second Lien Lenders on consensual out-of-court amend & extend
10-Jun-20
$3.9 billion
Target:
Global collaboration agreement with Genmab A/S
Acquiror:
AbbVie, Inc
Advised AbbVie, Inc, an NYSE-listed global biopharmaceutical company, on a broad collaboration with Genmab A/S, a leading Danish-listed biotechnology company, to jointly develop and commercialise three next-generation bispecific antibody programs